tbuckley/cabot-search huggingface dataset:
Restriction fragment length polymorphism associated with the pro alpha 2(I) gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta.
Authors: P Tsipouras, J C Myers, F Ramirez, D J Prockop
Journal: Journal of Clinical Investigation (1983)

One cloned complementary DNA and one genomic subclone were used to detect restriction fragment length polymorphism associated with the pro alpha 2(I) gene for human type I procollagen. The restriction fragments obtained from examination of 30-122 chromosomes confirmed previous indications that the pro alpha 2(I) gene is found in a single copy in the human haploid genome. One highly polymorphic site was detected with EcoRI in the 5'-half of the gene. The restriction site polymorphism at the site had an allelic frequency of 0.38, and it generated two fragments of 10.5 and 3.5 kilobase in homozygous individuals. The restriction fragment length polymorphism generated at the EcoRI site was used to study affected and non-affected individuals in four generations of a family with an autosomal dominant form of osteogenesis imperfecta. The data demonstrated a linkage of the phenotype to a pro alpha 2(I) allele with a lod score of 2.41 at a recombination fraction (theta) of 0. The data therefore provided presumptive evidence that osteogenesis imperfecta in this family is caused by a mutation in the pro alpha 2(I) gene or some contiguous region of the genome. The relatively high frequency of polymorphism at the EcoRI site makes it useful for studying a broad range of genetic disorders in which mutations in type I procollagen are suspected. In addition, the polymorphic site should provide useful markers for linkage studies with other loci located on human chromosome 7.
Velocity profiles and phasic flow patterns in the non-stenotic human left anterior descending coronary artery during cardiac surgery
Authors: F. Kajiya, S. Matsuoka, Y. Ogasawara, O. Hiramatsu, S. Kanazawa, Y. Wada, S. Tadaoka, K. Tsujioka, T. Fujiwara, M. Zamir
Journal: Cardiovascular Research (1993)

Objective: The aim was to investigate the phasic characteristics of normal human left coronary artery flow and velocity profiles across the vessel. Methods: The phasic characteristics of flow in the human left anterior descending coronary artery, the centreline flow velocities, and the velocity profiles were measured in 10 patients during corrective surgery for atrial septal defect after closure of the defect. None of these patients had any detectable coronary artery stenosis or left ventricular hypertrophy. Measurements were made with a 20 MHz 80 channel pulsed Doppler velocimeter. Results: The velocity waveform displayed a diastolic-predominant pattern with a systolic to diastolic velocity ratio of 0.29(SD 0.17). Reverse flow was observed in early systole in five patients and in mid to late systole in six patients. The values of peak Reynolds number, unsteadiness parameter, and pulsatility index were 504(198), 2.5(0.6), and 5.9(4.4) respectively. The velocity profiles during diastole showed considerable variability in shape, ranging from symmetrical to skewed to M shaped patterns. The peak wall shear rate was 765(250) s−1 on the epicardial wall of the vessel and 712(301) s−1 on the myocardial wall; the difference was not statistically significant. Conclusions: The velocity waveform displayed a diastolic-predominant pattern. Considerable variability in shape of the velocity profile was found and was perhaps due to the time evolution of the velocity profile within the diastolic time period. Cardiovascular Research 1993;27:845-850
Symptomatic pulmonary vein stenosis after catheter ablation of atrial fibrillation: Correlation with number of affected veins
Authors: Eduardo B. Saad, Yaariv Khaykin, J.David Burkhardt, Mandeep Bhargava, Cynthia P. Saad, Ahmad Abdul-Karim, Alejandro Perez-Lugones, Dianna Bash, Michelle Andrews-Williams, David O. Martin, Nassir F. Marrouche, Walid I. Saliba, Robert A. Schweikert, Andrea Natale
Journal: Journal of the American College of Cardiology (2003)
TO WHAT EXTENT CAN THE GYNECOLOGIST PREVENT AND CURE INSANITY IN WOMEN?
Authors: W. O. HENRY
Journal: JAMA (1907)

<h3>REVIEW OF LITERATURE.</h3> The question of the relationship existing between pelvic diseases in women and insanity is one which has occupied the attention of the profession many years, more particularly since 1857, when Loiseau presented a thesis on the subject, "Sympathetic Insanity," which caused considerable discussion, and also since the paper by Hergt, in 1870, on the subject, "Women's Diseases and Disturbances of the Mind." Although from that time to the present the subject has been discussed to some extent in medical societies and through medical journals, even yet great difference of opinion exists among gynecologists and alienists. When I read a paper before the Nebraska State Medical Society in 1898 on the subject, "Relations of Insanity and Pelvic Diseases in Women," there was little sympathy expressed by the members of the society and my conclusions then given, which more extensive experience has served to confirm, were not received with
Case 28-1968
Authors: Arnold S. Relman, Martin H. Flax
Journal: New England Journal of Medicine (1968)

Presentation of Case First admission. A fifty-eight-year-old woman was admitted to the hospital because of increasing edema.She had been well until four months previously, when there was the onset of progressive edema of the feet and hands, puffiness under the eyes and swelling of the abdomen. She noticed frothing of the urine, but no dysuria, oliguria or discoloration of the urine. One month before admission she entered another hospital. The blood pressure was 126 systolic, 80 diastolic. The urine gave a ++++ test for protein; the sediment contained 20 to 30 white cells and many hyaline and granular casts . . .
Epidermal lipid metabolism in psoriasis and lichen simplex
Authors: MARY F. COOPER, HELEN McGRATH, SAM SHUSTER
Journal: British Journal of Dermatology (1976)

Journal Article Epidermal lipid metabolism in psoriasis and lichen simplex Get access MARY F. COOPER, MARY F. COOPER Department of Dermatology, Wellcome Laboratories for Research into Skin Disease, University of Newcastle‐upon‐Tyne, Newcastle‐upon‐Tyne NE1 4LP Dr M.F.Cooper, Department of Dermatology, The Royal Victoria Infirmary, Newcastle‐upon‐Tyne NE1 4LP. Search for other works by this author on: Oxford Academic Google Scholar HELEN McGRATH, HELEN McGRATH Department of Dermatology, Wellcome Laboratories for Research into Skin Disease, University of Newcastle‐upon‐Tyne, Newcastle‐upon‐Tyne NE1 4LP Search for other works by this author on: Oxford Academic Google Scholar SAM SHUSTER SAM SHUSTER Department of Dermatology, Wellcome Laboratories for Research into Skin Disease, University of Newcastle‐upon‐Tyne, Newcastle‐upon‐Tyne NE1 4LP Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 94, Issue 4, 1 April 1976, Pages 369–378, https://doi.org/10.1111/j.1365-2133.1976.tb06114.x Published: 01 April 1976
Rapid Changes in the Scintigraphic Pattern in Tc-99m DPD Whole-Body Scanning in Metabolic Bone Disease
Authors: THOMAS LEITHA
Journal: Clinical Nuclear Medicine (1998)

The author describes a patient with generalized bone pain with metabolic bone disease who was erroneously diagnosed as having metastatic disease. The teaching points of this case include 1) the rapid changes in the abnormalities in bone scintigraphy in untreated osteomalacia ; 2) the discrepancy between the normal appearance of the spine and severe lesions in other bones in metabolic bone disease, which could be used as a decision tool for the differential diagnosis; and finally 3) the necessity to correlate target lesions in bone scanning with conventional radiography even in patients with a high suspicion for generalized metastatic disease.
Cardiovascular Manifestations in Argemone Mexicana Poisoning (Epidemic Dropsy)
Authors: L. M. SANGHVI, S. N. MISRA, T. K. BOSE
Journal: Circulation (1960)

Cardiovascular manifestations have been studied in 11 patients with argemone oil poisoning. Tachycardia, alterations in the heart sounds, cardiac enlargement, or electrocardiographic and ballistocardiographic changes indicated myocardial involvement in every case. The latter was suggestive of a nonspecific type of myocarditis and was considered to be of a minor nature. The prominent manifestations included dyspnea, edema, hepatic enlargement, and pulmonary congestion. The last 3 were probably due to capillary dilatation, whereas the cause of dyspnea was uncertain. These manifestations suggested the presence of cardiac failure, which, however, was considered unlikely except in 1 case.
Abstract 5053: Preliminary results from the Reproducibility Project: Cancer Biology - a replication of 50 high-impact cancer cell biology papers from 2010-2012
Authors: Gunn William, Elizabeth Iorns, Elizabeth Silva, Brian Nosek
Journal: Cancer Research (2014)

Abstract The lack of reproducibility of preclinical research is a significant and growing problem which slows basic research and leads to fruitless clinical trials. An increasing number of reports have found discrepancies in published preclinical studies across scientific disciplines. For example: * Amgen found that 47 of 53 “landmark” oncology publications could not be reproduced. * Bayer found that their internal results contradicted academic publications in 43 of 67 oncology and cardiovascular projects. * Dr. John Ioannidis and his colleagues found that of 432 publications purporting sex differences in hypertension, multiple sclerosis, or lung cancer, only one data set was reproducible. These studies, and the many others that report similar results, highlight a significant problem in the development of new therapies to treat disease. With increasing reports of discrepancies in preclinical publications, pharmaceutical companies are being forced to re-evaluate their reliance on academic research. In fact, Bayer recently decided to halt nearly two-thirds of target-validation projects.In this session, we'll report the work we have done to address this issue. We will bring together researchers and representatives from funders and publishers to discuss the issue of reproducibility. We will share funder and publisher initiatives to promote reproducibility and also discuss research practices that lead to more reproducible research such as using proper statistical tests, reporting all experimental data, experimental blinding, and identification and validation of research reagents. We'll also share preliminary results from an Arnold Foundation-funded study to replicate the 50 most high impact cancer biology studies from 2010-1012. Reproducibility ResearchAmgen47 of 53 “landmark” oncology publications could not be reproducedBayerinternal results contradicted academic publications in 43 of 67 oncology and cardiovascular projectsDr. John Ioannidis and colleagues432 publications purporting sex differences in hypertension, multiple sclerosis, or lung cancer, only one data set was reproducible Note: This abstract was not presented at the meeting. Citation Format: Gunn William, Elizabeth Iorns, Elizabeth Silva, Brian Nosek. Preliminary results from the Reproducibility Project: Cancer Biology - a replication of 50 high-impact cancer cell biology papers from 2010-2012. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5053. doi:10.1158/1538-7445.AM2014-5053
Human T-cell leukemia virus type 2 induces survival and proliferation of CD34+ TF-1 cells through activation of STAT1 and STAT5 by secretion of interferon-γ and granulocyte macrophage–colony-stimulating factor
Authors: Chiara Bovolenta, Elisabetta Pilotti, Massimiliano Mauri, Marco Turci, Paolo Ciancianaini, Paola Fisicaro, Umberto Bertazzoni, Guido Poli, Claudio Casoli
Journal: Blood (2002)
73 Adaptive renal ABC transporter expression in common bile duct-ligated mice
Authors: M. Wagner, P. Fickert, G. Zollner, D. Silbert, A. Fuchsbichler, J. Gumhold, J.D. Schuetz, F.J. Gonzalez, K. Zatloukal, H.U. Marschall, H. Denk, M. Trauner
Journal: Journal of Hepatology (2004)
The American College of Surgeons and the AMA
Authors: Grant V. Rodkey
Journal: JAMA (1991)

<h3>To the Editor.—</h3> In 1980, because of policy differences and an unsympathetic relationship between the chief executive officers of the two organizations, the American College of Surgeons withdrew its delegate to the House of Delegates of the American Medical Association (AMA). The House of Delegates voted to keep a seat open for the college—as it remains to the present. The current House of Delegates consists of 348 representatives of state medical societies, the military and public health service, US medical schools, medical students, residents, young physicians, hospital medical staffs, and each of 78 specialty society organizations. The only major medical professional group not represented is the American College of Surgeons. The medical profession lacks a unified and effective political expression of informed opinions and recommendations on issues of health care policy. As a result, the American public, our patients, now have a less effective system of health care than might
Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom.
Authors: C R Buchanan, M A Preece, R D Milner
Journal: BMJ (1991)

To determine the cause of death and incidence of neoplasia in patients treated with human pituitary growth hormone.A long term cohort study established to receive details of death certification and tumour registrations through the Office of Population Censuses and Surveys and NHS central register.All patients (1246 male, 662 female) treated for short stature with pituitary growth hormone under the Medical Research Council working party and health services human growth hormone committee.Death or development of neoplasia.110 patients died (68 male, 42 female; aged 0.9-57 years) from 1972 to 1990. Fifty three death were from neoplasia responsible for growth hormone deficiency (27 craniopharyngioma, 24 other intracranial tumour, two leukaemia); two from histiocytosis X; and 13 from pituitary insufficiency. Six patients died of Creutzfeldt-Jakob disease, six of other neurological disorders, and eight of acute infection. Other deaths were apparently unrelated to growth hormone deficiency or its treatment. Seventeen tumours (in 16 patients) were identified during or after growth hormone treatment. Four were in patients with previous intracranial neoplasia and two were after cranial irradiation. Thirteen were intracranial, the others being Hodgkin's lymphoma, osteosarcoma, carcinoma of colon, and basal cell carcinoma.Recurrence or progression of intracranial tumours and potentially avoidable metabolic consequences of hypopituitarism were the main causes of death. Growth hormone treatment probably did not contribute to new tumour development. Creutzfeldt-Jakob disease after pituitary growth hormone treatment continues to occur in the United Kingdom. This cohort must remain under long term review.
Creative Part-Time Faculty Arrangements
Authors: Bonnie J. Tesch
Journal: Annals of Internal Medicine (1994)

Letters15 February 1994Creative Part-Time Faculty ArrangementsBonnie J. Tesch, MD and Ann B. Nattinger, MD, MPHBonnie J. Tesch, MDMedical College of Wisconsin; Milwaukee, WI 53226Search for more papers by this author and Ann B. Nattinger, MD, MPHMedical College of Wisconsin; Milwaukee, WI 53226Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-120-4-199402150-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In response to the study by Levinson and colleagues [1], we describe a model that has worked well at the Medical College of Wisconsin.In July 1985, the Division of General Internal Medicine required additional personnel. Three female physicians independently requested part-time work because of family responsibilities. The division chief and the administration agreed to allow all three women to work part-time, which was defined as 50% to 70% of full-time. The benefits included prorated vacation and sick leave, with the option of participating in the retirement plan. Malpractice was not paid, and no policy was created ...REFERENCE1. Levinson W, Kaufman K, Bickel J. Part-time faculty in academic medicine: present status and future challenges. Ann Intern Med. 1993; 119:220-5. Google Scholar Author, Article, and Disclosure InformationAuthors: Bonnie J. Tesch, MD; Ann B. Nattinger, MD, MPHAffiliations: Medical College of Wisconsin; Milwaukee, WI 53226 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOpting In: Part-time Careers in Academic Medicine 15 February 1994Volume 120, Issue 4Page: 346-347 ePublished: 15 August 2000 Issue Published: 15 February 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Seasonal Variation in <i>TP53 R249S</i> -Mutated Serum DNA with Aflatoxin Exposure and Hepatitis B Virus Infection
Authors: Stéphanie Villar, Emilie Le Roux-Goglin, Doriane A. Gouas, Amelie Plymoth, Gilles Ferro, Mathieu Boniol, Myriam Lereau, Ebrima Bah, Andrew J. Hall, Christopher P. Wild, Maimuna Mendy, Helene Norder, Marianne van der Sande, Hilton Whittle, Marlin D. Friesen, John D. Groopman, Pierre Hainaut
Journal: Environmental Health Perspectives (2011)

Chronic hepatitis B virus (HBV) infection and dietary aflatoxin B1 (AFB1) exposure are etiological factors for hepatocellular carcinoma (HCC) in countries with hot, humid climates. HCC often harbors a TP53 (tumor protein p53) mutation at codon 249 (R249S). In chronic carriers, 1762T/1764A mutations in the HBV X gene are associated with increased HCC risk. Both mutations have been detected in circulating cell-free DNA (CFDNA) from asymptomatic HBV carriers.We evaluated seasonal variation in R249S and HBV in relation to AFB1 exposure.R249S was quantitated by mass spectrometry in CFDNA in a cross-sectional survey of 473 asymptomatic subjects (237 HBV carriers and 236 noncarriers) recruited in three villages in the Gambia over a 10-month period. 1762T/1764A HBV mutations were detected by quantitative polymerase chain reaction. In addition, the HBV S gene was sequenced in 99 subjects positive for HBV surface antigen (HBsAg).We observed a seasonal variation of serum R249S levels. Positivity for R249S and average concentration were significantly higher in HBsAg-positive subjects surveyed during April-July (61%; 5,690 ± 11,300 R249S copies/mL serum) than in those surveyed October-March [32% and 480 ± 1,030 copies/mL serum (odds ratio = 3.59; 95% confidence interval: 2.05, 6.30; p < 0.001)]. Positivity for HBV e antigen (HBeAg) (a marker of HBV replication) and viral DNA load also varied seasonally, with 15-30% of subjects surveyed between April and June HBeAg positive, compared with < 10% surveyed during other months. We detected 1762T/1764A mutations in 8% of carriers, half of whom were positive for R249S. We found HBV genotype E in 95 of 99 HBsAg-positive subjects.R249S is detectable in CFDNA of asymptomatic subjects. Evidence of temporal and quantitative variations suggests an interaction among AFB1 exposure, HBV positivity, and replication on TP53 mutation formation or persistence.
Some Thoughts about the Evaluation of Non-Clinical Functional Magnetic Resonance Imaging
Authors: Jennifer J. Kulynych
Journal: The American Journal of Bioethics (2007)

"Some Thoughts about the Evaluation of Non-Clinical Functional Magnetic Resonance Imaging." The American Journal of Bioethics, 7(9), pp. 57–58 ∗The views expressed are solely those of the author and do not reflect the views of The Johns Hopkins Hospital or The Johns Hopkins University. Notes 1. The statutory term “medical device” in the Federal Food, Drug, and Cosmetic Act applies to devices intended for use in the diagnosis of disease or other conditions, or in the treatment or prevention of disease. 21 U.S.C. § 321(h)(2). A “clinical investigation” under FDA regulations is an experiment involving a regulated product, where the experiment must either meet requirements for prior submission to FDA, or where the results are intended to be submitted to, or held for inspection by, FDA. 21 C.F.R. § § 50.3(c), 56.102(c).
Just a little scratch?
Authors: J. Cohn
Journal: BMJ (2009)

I learnt the importance of a ready supply of blood at the age of 16, when my best friend needed daily blood transfusions. All of us friends wanted to help, but ideals and enthusiasm could not bridge the age gap, and we were left with a vague undertaking to become blood donors when we grew up. 

A fortuitous blood drive during my first year of university had me embarking on a donating career that has spanned time and continents. Over that time I have been in remarkably good health, my drug use has been limited to nicotine (now abandoned, mercifully), and medically sanctioned quantities of alcohol. My extracurricular activities have been conservative, not to say prudish. So, you would think that I would be an ideal candidate as a blood donor, notwithstanding my bog …
Plasma exchange in psoriatic erythroderma
Authors: A. Rebora, G. Virno, ESTER Aratari, Daniela Aratari, R. Adnami, P. Strada
Journal: British Journal of Dermatology (1982)

Journal Article Plasma exchange in psoriatic erythroderma Get access A. Rebora, A. Rebora Clinica Dermosifilopatica II, A. Universita degli Studi, Genova, Italy Search for other works by this author on: Oxford Academic Google Scholar G. Virno, G. Virno Clinica Dermosifilopatica II, A. Universita degli Studi, Genova, Italy Search for other works by this author on: Oxford Academic Google Scholar ESTER Aratari, ESTER Aratari Clinica Dermosifilopatica II, A. Universita degli Studi, Genova, Italy Search for other works by this author on: Oxford Academic Google Scholar Daniela Aratari, Daniela Aratari Clinica Dermosifilopatica II, A. Universita degli Studi, Genova, Italy Search for other works by this author on: Oxford Academic Google Scholar R. Adnami, R. Adnami Serviziu di Immunoematologia e Trasfusionale, Ospcdale Galliera, Genova, Italy Search for other works by this author on: Oxford Academic Google Scholar P. Strada P. Strada Serviziu di Immunoematologia e Trasfusionale, Ospcdale Galliera, Genova, Italy Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 106, Issue 1, 1 January 1982, Pages 119–120, https://doi.org/10.1111/j.1365-2133.1982.tb00914.x Published: 01 January 1982